Mechanism of Action
CCK Receptor Subtypes (CCK1 and CCK2)
CCK acts through two Gq-coupled receptor subtypes. CCK1R (peripheral) is expressed in gallbladder, pancreas, vagal afferents, and enteric neurons, mediating GI effects and peripheral satiety signaling. CCK2R (gastrin receptor) is expressed in the stomach and CNS, mediating gastric acid regulation and central anxiogenic/analgesic effects. Both receptors activate PLC, IP3, and intracellular calcium pathways.
Satiety and Meal Termination
Post-prandial CCK release activates CCK1R on vagal afferent neurons, transmitting fullness signals to the nucleus tractus solitarius and hypothalamus. This shortens meal duration and reduces meal size without affecting long-term appetite set points. The satiety signal is potentiated by gastric distension and attenuated in CCK1R-deficient animals and humans, who become obese.
CNS and Anxiogenic Effects
CCK-4, a tetrapeptide fragment, reliably produces anxiety and panic attacks in humans through CCK2R, making it a validated anxiogenic tool in research. Conversely, CCK1R activation in limbic regions may contribute to satiety-associated reward. The dual anxiogenic (CCK2R) vs. neutral-to-anxiolytic (CCK1R) receptor pharmacology makes CCK system highly context-dependent.
Research Summary
Obesity and Satiety
HumanCCK infusion consistently reduces food intake in lean and obese humans. However, adaptation to repeated CCK exposure limits long-term anti-obesity utility of native CCK. CCK1R agonists with longer half-lives are in pharmaceutical development for obesity, targeting the satiety pathway without rapid tachyphylaxis.
Gallbladder and Pancreatic Function
HumanCCK-8 (Sincalide) has decades of clinical use for gallbladder contraction testing and for augmenting cholecystography. IV CCK-8 produces measurable gallbladder ejection fraction, useful diagnostically. Pancreatic secretion stimulation is used to assess exocrine pancreatic function in suspected insufficiency.
Pain Modulation
AnimalCCK-8 in the spinal cord modulates opioid analgesia: CCK2R activation in the dorsal horn reduces opioid-induced analgesia (the "anti-opioid" effect), contributing to morphine tolerance. CCK2R antagonists enhance opioid analgesia and reduce tolerance in animal models, representing a potential adjunct in pain management.
Calculate your CCK dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Satiety research | 20-100 ng/kg | Pre-meal infusion | Intravenous |
| Gallbladder stimulation | 0.02 mcg/kg | Single diagnostic dose | Slow IV infusion (over 30 min) |
| CNS/anxiety research | 50-100 mcg (CCK-4) | Single dose | IV bolus (human panic studies) |
Native CCK has a very short half-life. Clinical diagnostic use (Sincalide) is well established. Research into longer-acting CCK1R agonists for obesity is ongoing.
Interactions
Safety Profile
CCK-8 (Sincalide) has extensive clinical safety data from decades of diagnostic use. Common effects include mild cramping, nausea, and urgency to defecate, reflecting its GI smooth muscle actions. Rapid IV injection can cause dizziness and hypotension. CCK-4 reliably produces anxiety and panic symptoms in most individuals and is only used experimentally. No significant organ toxicity has been identified.
References
- [1]Gibbs J, Young RC, Smith GP. Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol. 1973;84(3):488-495.
- [2]Crawley JN, Corwin RL. Biological actions of cholecystokinin. Peptides. 1994;15(4):731-755.
- [3]Muller EE, Pelleymounter MA. CCK-A receptor agonism: pharmacologic opportunities for the treatment of obesity. Curr Top Med Chem. 2002.